. 2021 Feb 27;11(2):42. doi: 10.1038/s41408-021-00434-2

Table 2.

Multivariable analysis of the incidence of severe cGVHD, OS, NRM, and relapse in the training cohort.

Covariates	Severe chronic GVHD^a				OS				NRM^a		Relapse^a
	N	ScGVHD	HR (95% CI)	P	N	death	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Genetic risk
Low-risk group	190	26	Ref.		190	97	Ref.		Ref.		Ref.
High-risk group	52	17	2.48 (1.33–4.64)	0.004	52	27	1.09 (0.70–1.69)	0.697	1.34 (0.68–2.65)	0.402	0.90 (0.52–1.57)	0.710
Age	242	43	1.01 (0.98–1.03)	0.622	242	124	1.02 (1.00–1.03)	0.041	1.04 (1.01–1.07)	0.006	1.00 (0.98–1.02)	0.754
Recipient sex
Female	93	19	Ref.		93	48	Ref.		Ref.		Ref.
Male	149	24	0.88 (0.47–1.64)	0.694	149	76	1.00 (0.69–1.45)	0.979	1.52 (0.80–2.90)	0.199	0.77 (0.49–1.21)	0.252
Donor sex
Female	74	21	Ref.		74	38	Ref.		Ref.		Ref.
Male	168	22	0.5 (0.29–0.98)	0.042	168	86	1.07 (0.72–1.58)	0.741	0.95 (0.50–1.78)	0.863	0.93 (0.57–1.49)	0.755
Donor
Matched donor	179	34	Ref.		179	91	Ref.		Ref.		Ref.
Mismatched donor	63	9	1.82 (0.76–4.08)	0.180	63	33	1.45 (0.91–2.32)	0.115	2.33 (1.08–5.03)	0.032	0.92 (0.51–1.66)	0.772
Disease type
Myeloid^b	102	20	Ref.		102	47	Ref.		Ref.		Ref.
Lymphoid^c	140	23	1.05 (0.57–1.95)	0.869	140	77	1.25 (0.86–1.82)	0.238	0.78 (0.43–1.43)	0.419	2.26 (1.38–3.71)	0.001
ATG
No	117	32	Ref.		117	68	Ref.		Ref.		Ref.
Yes	125	11	0.26 (0.11–0.59)	0.001	125	56	0.68 (0.45–1.03)	0.067	0.49 (0.24–1.02)	0.057	0.86 (0.52–1.42)	0.559

ATG antithymocyte globulin, CI confidence interval, HR hazard ratio, ScGVHD severe chronic graft-versus-host disease.

^aHR and P value from cause-specific Cox models for competing risk. Death without scGVHD was taken as the competing event for scGVHD. NRM and relapse were treated as competing events.

^bMyeloid: acute myeloid leukemia and myelodysplastic and myeloproliferative syndromes.

^cLymphoid: acute lymphoblastic leukemia, chronic lymphocytic leukemia, T/B cell lymphoma, and multiple myeloma.